Thrombin	B-protein
and	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B-protein
cross-linking	O
for	O
CD69	B-protein
expression	O
and	O
interleukin	O
2	O
production	O
.	O

Thrombin	B-protein
stimulation	O
of	O
the	O
T	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	B-protein
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	B-protein
fluorophosphate-thrombin	I-protein
failed	O
to	O
increase	O
[	O
Ca2+	O
]	O
i	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	B-protein
III	I-protein
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
synthetic	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	B-protein
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	B-protein
mass	I-protein
40	I-protein
,	I-protein
42	I-protein
,	I-protein
70	I-protein
,	I-protein
120	I-protein
,	I-protein
and	I-protein
130	I-protein
kDa	I-protein
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2+	O
mobilization	O
.	O

Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B-protein
activated	O
the	O
nuclear	B-protein
factor	I-protein
NF-kB	I-protein
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
HPB.ALL	I-cell_line
and	O
the	O
erythroleukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
were	O
responsive	O
to	O
thrombin	B-protein
,	O
whereas	O
others	O
such	O
as	O
THP1	B-cell_line
,	O
a	O
myelomonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
BL2	B-cell_line
,	I-cell_line
a	O
Burkitt	B-cell_line
lymphoma	I-cell_line
were	O
refractory	O
to	O
thrombin	B-protein
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	B-protein
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B-protein
and	O
TRP	O
enhanced	O
CD69	B-protein
expression	O
and	O
interleukin	B-protein
2	I-protein
production	O
induced	O
by	O
T	B-protein
cell	I-protein
receptor	I-protein
cross-linking	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
peripheral	O
blood	O
lymphocytes	B-cell_type
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B-protein
as	O
a	O
potential	O
regulator	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

THz	NULL
Journat	NULL
or	NULL
Brorocicat	NULL
©	NULL
1994	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

269	NULL
,	NULL
No	NULL
.	NULL

11	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
18	NULL
,	NULL
pp	NULL
.	NULL

8517-8528	NULL
,	NULL
1994	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Thrombin	NULL
and	NULL
Thrombin	NULL
Receptor	NULL
Agonist	NULL
Peptide	NULL
Induce	NULL
Early	NULL
Events	NULL
of	NULL
T	NULL
Cell	NULL
Activation	NULL
and	NULL
Synergize	NULL
with	NULL
TCR	NULL
Cross-linking	NULL
for	NULL
CD69	NULL
Expression	NULL
and	NULL
Interleukin	NULL
2	NULL
Production*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
September	NULL
24	NULL
,	NULL
1993	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
December	NULL
9	NULL
,	NULL
1993	NULL
)	NULL
Bernard	NULL
Mari	NULL
,	NULL
Veronique	NULL
Imbert	NULL
,	NULL
Nathalie	NULL
Belhacene	NULL
,	NULL
Dariush	NULL
Farahi	NULL
Far	NULL
,	NULL
Jean-Francois	NULL
Peyron	NULL
,	NULL
Jacques	NULL
Pouysségurt	NULL
,	NULL
Ellen	NULL
Van	NULL
Obberghen-Schilling	NULL
?	NULL

,	NULL
Bernard	NULL
Rossi	NULL
,	NULL
and	NULL
Patrick	NULL
Auberger	NULL
$	NULL
§	NULL
From	NULL
the	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
)	NULL
U364	NULL
,	NULL
Faculté	NULL
de	NULL
Médecine	NULL
,	NULL
Avenue	NULL
de	NULL
Vallombrose	NULL
,	NULL
06107	NULL
Nice	NULL
,	NULL
Cedex	NULL
2	NULL
,	NULL
France	NULL
and	NULL
the	NULL
{	NULL
Centre	NULL
de	NULL
Biochimie	NULL
,	NULL
Centre	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique-INSERM	NULL
,	NULL
Pare	NULL
Valrose	NULL
,	NULL
06034	NULL
Nice	NULL
,	NULL
Cedex	NULL
France	NULL
Thrombin	NULL
stimulation	NULL
of	NULL
the	NULL
T	NULL
leukemic	NULL
cell	NULL
line	NULL
Jurkat	NULL
induced	NULL
a	NULL
transient	NULL
increase	NULL
in	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
.	NULL

Proteolytic	NULL
activity	NULL
of	NULL
the	NULL
enzyme	NULL
was	NULL
required	NULL
for	NULL
this	NULL
effect	NULL
since	NULL
diisopropyl	NULL
fluorophosphate-thrombin	NULL
failed	NULL
to	NULL
increase	NULL
[	NULL
Ca®*	NULL
]	NULL
)	NULL
;	NULL
.	NULL

Furthermore	NULL
,	NULL
hirudin	NULL
and	NULL
anti-thrombin	NULL
III	NULL
inhibited	NULL
the	NULL
thrombin-induced	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
rise	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
synthetic	NULL
thrombin	NULL
receptor	NULL
agonist	NULL
peptide	NULL
(	NULL
TRP	NULL
)	NULL
of	NULL
7	NULL
residues	NULL
(	NULL
SFLLRNP	NULL
)	NULL
was	NULL
found	NULL
to	NULL
be	NULL
as	NULL
effective	NULL
as	NULL
thrombin	NULL
for	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
mobilization	NULL
,	NULL
and	NULL
both	NULL
agonists	NULL
induced	NULL
Ca	NULL
``	NULL
release	NULL
exclusively	NULL
from	NULL
internal	NULL
stores	NULL
.	NULL

Thrombin	NULL
stimulated	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
proteins	NULL
of	NULL
molecular	NULL
mass	NULL
40	NULL
,	NULL
42	NULL
,	NULL
70	NULL
,	NULL
120	NULL
,	NULL
and	NULL
130	NULL
kDa	NULL
.	NULL

There	NULL
was	NULL
a	NULL
good	NULL
correlation	NULL
between	NULL
thrombin-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
latter	NULL
three	NULL
proteins	NULL
and	NULL
Ca*	NULL
``	NULL
*	NULL
mobilization	NULL
.	NULL

Thrombin	NULL
and	NULL
TRP	NULL
also	NULL
caused	NULL
translocation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
.	NULL

As	NULL
a	NULL
likely	NULL
consequence	NULL
of	NULL
these	NULL
events	NULL
,	NULL
thrombin	NULL
activated	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-kB	NULL
.	NULL

Several	NULL
cell	NULL
lines	NULL
of	NULL
hematopoietic	NULL
origin	NULL
including	NULL
the	NULL
leukemic	NULL
T	NULL
cell	NULL
line	NULL
HPB.ALL	NULL
and	NULL
the	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
K562	NULL
were	NULL
responsive	NULL
to	NULL
thrombin	NULL
,	NULL
whereas	NULL
others	NULL
such	NULL
as	NULL
THP1	NULL
,	NULL
a	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
BL2	NULL
,	NULL
a	NULL
Burkitt	NULL
lymphoma	NULL
were	NULL
refractory	NULL
to	NULL
thrombin	NULL
or	NULL
TRP	NULL
stimulation	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
the	NULL
thrombin	NULL
response	NULL
in	NULL
the	NULL
different	NULL
cell	NULL
types	NULL
paralleled	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
.	NULL

We	NULL
found	NULL
that	NULL
activation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
phytohemagglutinin	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
inhibition	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
and	NULL
to	NULL
a	NULL
concomitant	NULL
loss	NULL
of	NULL
the	NULL
thrombin	NULL
response	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
thrombin	NULL
and	NULL
TRP	NULL
enhanced	NULL
CD69	NULL
expression	NULL
and	NULL
interleukin	NULL
2	NULL
production	NULL
induced	NULL
by	NULL
T	NULL
cell	NULL
receptor	NULL
cross-linking	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

These	NULL
findings	NULL
highlight	NULL
the	NULL
role	NULL
of	NULL
thrombin	NULL
as	NULL
a	NULL
potential	NULL
regulator	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

The	NULL
serine	NULL
protease	NULL
a-thrombin	NULL
(	NULL
thrombin	NULL
)	NULL
is	NULL
generated	NULL
from	NULL
the	NULL
zymogen	NULL
prothrombin	NULL
during	NULL
blood	NULL
coagulation	NULL
.	NULL

In	NULL
addition	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
)	NULL
,	NULL
Grant	NULL
6834	NULL
from	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
contre	NULL
le	NULL
Cancer	NULL
,	NULL
and	NULL
by	NULL
the	NULL
Groupement	NULL
des	NULL
Entre-prises	NULL
Francaises	NULL
dans	NULL
la	NULL
Lutte	NULL
contre	NULL
le	NULL
Cancer	NULL
(	NULL
GEFLUC	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertise-ment	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
INSERM	NULL
U364	NULL
,	NULL
Faculté	NULL
de	NULL
Médecine	NULL
,	NULL
Avenue	NULL
de	NULL
Vallombrose	NULL
,	NULL
06107	NULL
Nice-cedex	NULL
02	NULL
,	NULL
France	NULL
.	NULL

to	NULL
its	NULL
role	NULL
in	NULL
the	NULL
conversion	NULL
of	NULL
fibrinogen	NULL
to	NULL
fibrin	NULL
,	NULL
thrombin	NULL
exhibits	NULL
numerous	NULL
cellular	NULL
effects	NULL
(	NULL
Shuman	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

It	NULL
is	NULL
to	NULL
date	NULL
,	NULL
the	NULL
most	NULL
potent	NULL
stimulator	NULL
of	NULL
platelet	NULL
aggregation	NULL
(	NULL
Berndt	NULL
and	NULL
Philips	NULL
,	NULL
1981	NULL
;	NULL
Siess	NULL
,	NULL
1989	NULL
;	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
)	NULL
,	NULL
and	NULL
other	NULL
thrombin	NULL
responsive	NULL
cells	NULL
include	NULL
endothelial	NULL
cells	NULL
,	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
,	NULL
and	NULL
fibroblasts	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
thrombin	NULL
receptor	NULL
belonging	NULL
to	NULL
the	NULL
seven-transmembrane	NULL
domain	NULL
receptor	NULL
family	NULL
has	NULL
been	NULL
cloned	NULL
by	NULL
expression	NULL
in	NULL
Xenopus	NULL
oocytes	NULL
(	NULL
Vu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991a	NULL
;	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Receptor	NULL
activation	NULL
occurs	NULL
through	NULL
a	NULL
unique	NULL
mechanism	NULL
involving	NULL
proteolysis	NULL
by	NULL
thrombin	NULL
at	NULL
a	NULL
specific	NULL
site	NULL
in	NULL
the	NULL
N-terminal	NULL
portion	NULL
of	NULL
the	NULL
receptor	NULL
,	NULL
unmasking	NULL
a	NULL
sequence	NULL
which	NULL
functions	NULL
as	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
receptor	NULL
(	NULL
Vu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991a	NULL
,	NULL
1991b	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
synthetic	NULL
pep-tides	NULL
corresponding	NULL
to	NULL
this	NULL
sequence	NULL
mimic	NULL
the	NULL
action	NULL
of	NULL
thrombin	NULL
(	NULL
Vu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Vouret-Cravieri	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
,	NULL
1993	NULL
;	NULL
Hung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992a	NULL
;	NULL
Troyer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Mac	NULL
Namara	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
platelets	NULL
,	NULL
thrombin	NULL
induces	NULL
the	NULL
activation	NULL
of	NULL
phospholipase	NULL
C	NULL
and	NULL
the	NULL
subsequent	NULL
generation	NULL
of	NULL
inositol	NULL
trisphos-phate	NULL
:	NULL
and	NULL
diacylglycerol	NULL
,	NULL
which	NULL
result	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
[	NULL
Ca*+	NULL
]	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
(	NULL
Siess	NULL
,	NULL
1989	NULL
;	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
phorbol	NULL
esters	NULL
act	NULL
in	NULL
synergy	NULL
with	NULL
the	NULL
thrombin-induced	NULL
mobilization	NULL
of	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
to	NULL
induce	NULL
the	NULL
full	NULL
response	NULL
.	NULL

Furthermore	NULL
,	NULL
rapid	NULL
changes	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
status	NULL
of	NULL
platelets	NULL
proteins	NULL
were	NULL
observed	NULL
after	NULL
thrombin	NULL
treatment	NULL
(	NULL
Golden	NULL
and	NULL
Brugge	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
fibroblasts	NULL
,	NULL
G	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
transduce	NULL
thrombin	NULL
activation	NULL
of	NULL
phosphoinositide-specific	NULL
phospholipase	NULL
C	NULL
and	NULL
to	NULL
induce	NULL
DNA	NULL
synthesis	NULL
in	NULL
a	NULL
pertussis	NULL
toxin-sensitive	NULL
manner	NULL
(	NULL
Chambard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
also	NULL
requires	NULL
two	NULL
signals	NULL
,	NULL
the	NULL
first	NULL
one	NULL
proceeds	NULL
via	NULL
the	NULL
phosphoinositol	NULL
pathway	NULL
(	NULL
Imboden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
and	NULL
the	NULL
second	NULL
can	NULL
be	NULL
delivered	NULL
by	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
through	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
Davis	NULL
and	NULL
Lipsky	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
platelets	NULL
,	NULL
these	NULL
two	NULL
signals	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
induce	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Protein	NULL
tyrosine	NULL
kinases	NULL
of	NULL
the	NULL
src	NULL
family	NULL
have	NULL
also	NULL
been	NULL
implicated	NULL
as	NULL
a	NULL
primary	NULL
step	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Veillette	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Samelson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
relative	NULL
roles	NULL
of	NULL
G	NULL
proteins	NULL
versus	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
in	NULL
this	NULL
process	NULL
is	NULL
still	NULL
controversial	NULL
(	NULL
Harnett	NULL
and	NULL
Rigley	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

Although	NULL
thrombin	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
to	NULL
be	NULL
mitogenic	NULL
for	NULL
mouse	NULL
splenocytes	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1976	NULL
)	NULL
,	NULL
current	NULL
knowledge	NULL
regarding	NULL
its	NULL
effects	NULL
on	NULL
T	NULL
cell	NULL
activation	NULL
is	NULL
scant	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
on	NULL
the	NULL
effect	NULL
of	NULL
human	NULL
a	NULL
thrombin	NULL
on	NULL
'	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
:	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
TRP	NULL
,	NULL
thrombin	NULL
receptor	NULL
peptide	NULL
;	NULL
PHA	NULL
,	NULL
phyto-hemagglutinin	NULL
;	NULL
IL2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

8517	NULL
8518	NULL
both	NULL
short	NULL
and	NULL
long	NULL
term	NULL
events	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Materials-DFP	NULL
,	NULL
hirudin	NULL
,	NULL
and	NULL
anti-thrombin	NULL
III	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Highly	NULL
purified	NULL
human	NULL
a	NULL
«	NULL
-thrombin	NULL
(	NULL
3209	NULL
NIH	NULL
units/mg	NULL
)	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
J.	NULL
W.	NULL
Fenton	NULL
II	NULL
(	NULL
New	NULL
York	NULL
State	NULL
Department	NULL
of	NULL
Health	NULL
,	NULL
Albany	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

TRP	NULL
(	NULL
SFLLRNP	NULL
)	NULL
was	NULL
synthetized	NULL
by	NULL
Neosystem	NULL
(	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Cells-The	NULL
human	NULL
T	NULL
cell	NULL
lines	NULL
Jurkat	NULL
,	NULL
HPB.ALL	NULL
,	NULL
K562	NULL
,	NULL
THP1	NULL
,	NULL
and	NULL
BL-2	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
50	NULL
units/ml	NULL
penicillin	NULL
,	NULL
50	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
2	NULL
mm	NULL
L-glutamine	NULL
,	NULL
1	NULL
mm	NULL
pyruvate	NULL
,	NULL
and	NULL
0.1	NULL
um	NULL
2-mercaptoethanol	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Auberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
CD3~	NULL
T	NULL
cell	NULL
variant	NULL
was	NULL
obtained	NULL
by	NULL
fluo-rescence-activated	NULL
cell	NULL
sorting	NULL
.	NULL

Peripheral	NULL
Lymphocyte	NULL
Preparation-Human	NULL
peripheral	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
,	NULL
under	NULL
sterile	NULL
conditions	NULL
,	NULL
from	NULL
leukophoresis	NULL
samples	NULL
obtained	NULL
from	NULL
the	NULL
``	NULL
Centre	NULL
de	NULL
Transfusion	NULL
Sanguine	NULL
A.	NULL
Tzanck	NULL
``	NULL
(	NULL
St	NULL
Laurent	NULL
du	NULL
Var	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Purified	NULL
T	NULL
lymphocytes	NULL
were	NULL
obtained	NULL
by	NULL
rosetting	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Mari	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
preparation	NULL
was	NULL
assessed	NULL
by	NULL
both	NULL
flow	NULL
cytometry	NULL
for	NULL
CD2	NULL
,	NULL
CD3	NULL
,	NULL
CD4	NULL
,	NULL
and	NULL
CD8	NULL
expression	NULL
and	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
CD14	NULL
and	NULL
CD20	NULL
expression	NULL
and	NULL
finally	NULL
,	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
PHA-induced	NULL
[	NULL
°H	NULL
)	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Cytosolic	NULL
Calcium	NULL
Measurements-Cytoplasmic	NULL
free	NULL
calcium	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
using	NULL
the	NULL
fluorescent	NULL
dye	NULL
indo-1	NULL
(	NULL
Grienkiewitz	NULL
ef	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
and	NULL
an	NULL
ATC	NULL
3000	NULL
cytofluorograph	NULL
(	NULL
ODAM	NULL
,	NULL
Wissembourg	NULL
,	NULL
France	NULL
)	NULL
,	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
Auberger	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Tyrosine	NULL
Phosphorylation	NULL
and	NULL
Immunoblotting-Jurkat	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
per	NULL
condition	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
with	NULL
3	NULL
units/ml	NULL
human	NULL
thrombin	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
immunoblotting	NULL
of	NULL
protein	NULL
extracts	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Imbert	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
onto	NULL
Immobilon	NULL
membranes	NULL
(	NULL
Milli-pore	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
then	NULL
saturated	NULL
and	NULL
probed	NULL
with	NULL
an	NULL
anti-phosphotyrosine	NULL
mouse	NULL
mAb	NULL
(	NULL
4G10	NULL
,	NULL
U.B.1	NULL
.	NULL
)	NULL

at	NULL
1	NULL
ug/ml	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
addition	NULL
of	NULL
'**I-protein	NULL
A	NULL
and	NULL
autoradiography	NULL
.	NULL

PKC	NULL
Translocation-The	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
serum	NULL
free	NULL
RPMI	NULL
1640	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
human	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
,	NULL
TRP	NULL
(	NULL
100	NULL
pum	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
.	NULL

Following	NULL
a	NULL
10-min	NULL
incubation	NULL
,	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
at	NULL
0	NULL
°C	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

T	NULL
lymphocytes	NULL
were	NULL
homogenized	NULL
and	NULL
sonicated	NULL
in	NULL
a	NULL
solution	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
containing	NULL
0.25	NULL
m	NULL
sucrose	NULL
,	NULL
20	NULL
my	NULL
triethanolamine	NULL
,	NULL
2	NULL
mm	NULL
EDTA	NULL
,	NULL
0.5	NULL
mm	NULL
EGTA	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
10	NULL
ug/ml	NULL
pepstatin	NULL
,	NULL
and	NULL
1	NULL
mm	NULL
phe-nylmethylsulfonyl	NULL
fluoride	NULL
.	NULL

The	NULL
supernatant	NULL
,	NULL
obtained	NULL
after	NULL
centrifuga-tion	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
(	NULL
1	NULL
h	NULL
,	NULL
4	NULL
°C	NULL
)	NULL
,	NULL
represents	NULL
the	NULL
cytosolic	NULL
fraction	NULL
of	NULL
PKC	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
homogenization	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
particulate	NULL
protein	NULL
kinase	NULL
C	NULL
fraction	NULL
.	NULL

PKC	NULL
activity	NULL
was	NULL
then	NULL
enriched	NULL
on	NULL
DEAE	NULL
ion-exchange	NULL
columns	NULL
for	NULL
both	NULL
fractions	NULL
and	NULL
measured	NULL
as	NULL
previously	NULL
described	NULL
using	NULL
histone	NULL
HIIIS	NULL
as	NULL
substrate	NULL
(	NULL
Tanti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
assays	NULL
were	NULL
performed	NULL
for	NULL
30	NULL
min	NULL
at	NULL
20	NULL
°C	NULL
with	NULL
100	NULL
ul	NULL
of	NULL
the	NULL
indicated	NULL
fraction	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
250	NULL
ul	NULL
of	NULL
20	NULL
mm	NULL
Tris/HCl	NULL
buffer	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
containing	NULL
[	NULL
y-*2PJATP	NULL
(	NULL
5	NULL
uCi	NULL
;	NULL
50	NULL
um	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
magnesium	NULL
acetate	NULL
,	NULL
1	NULL
mm	NULL
CaCl	NULL
,	NULL
,	NULL
and	NULL
25	NULL
ug	NULL
of	NULL
histone	NULL
HIIIS	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
24	NULL
ug	NULL
of	NULL
phosphatidylserine	NULL
and	NULL
1.6	NULL
ug	NULL
of	NULL
1,2-diolein	NULL
(	NULL
Tanti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
samples	NULL
were	NULL
adsorbed	NULL
on	NULL
phosphocellulose	NULL
P81	NULL
paper	NULL
,	NULL
and	NULL
extensively	NULL
washed	NULL
in	NULL
1	NULL
%	NULL
HPO	NULL
,	NULL
solution	NULL
.	NULL

mRNA	NULL
Preparation	NULL
and	NULL
Northern	NULL
Blot	NULL
Analysis-Total	NULL
RNAs	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
different	NULL
cell	NULL
lines	NULL
by	NULL
acid	NULL
guanidium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
(	NULL
Chomezynski	NULL
and	NULL
Sacchi	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

RNA	NULL
aliquots	NULL
(	NULL
25	NULL
ug	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
under	NULL
denaturing	NULL
conditions	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
(	NULL
Hybond	NULL
N*	NULL
,	NULL
Amer-sham	NULL
,	NULL
France	NULL
)	NULL
.	NULL

The	NULL
thrombin	NULL
receptor	NULL
cDNA	NULL
or	NULL
actin	NULL
cDNA	NULL
probes	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Hybridiza-tion	NULL
was	NULL
performed	NULL
overnight	NULL
at	NULL
65	NULL
°C	NULL
and	NULL
the	NULL
filters	NULL
were	NULL
washed	NULL
at	NULL
65	NULL
°C	NULL
following	NULL
the	NULL
procedure	NULL
of	NULL
Church	NULL
and	NULL
Gilbert	NULL
(	NULL
1984	NULL
)	NULL
.	NULL

NF-kB	NULL
Activation-Jurkat	NULL
T	NULL
cells	NULL
(	NULL
10®/ml	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
thrombin	NULL
,	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
NF-KB	NULL
activation	NULL
.	NULL

Preparation	NULL
of	NULL
cellular	NULL
cytosolic	NULL
and	NULL
nuclear	NULL
fractions	NULL
were	NULL
made	NULL
by	NULL
the	NULL
procedure	NULL
of	NULL
Digman	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
,	NULL
modified	NULL
by	NULL
Osborn	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Assays	NULL
were	NULL
performed	NULL
using	NULL
an	NULL
oligonucleotide	NULL
with	NULL
the	NULL
consensus	NULL
NF-kB	NULL
motif	NULL
(	NULL
GATC-CAAGGGGACTTTCCATG	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
samples	NULL
(	NULL
10	NULL
ug	NULL
of	NULL
pro-tein	NULL
)	NULL
were	NULL
preincubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
ug/ml	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
.	NULL

The	NULL
labeled	NULL
oligonucleotides	NULL
were	NULL
then	NULL
added	NULL
for	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
A	NULL
425	NULL
40	NULL
425	NULL
3s	NULL
D	NULL
30	NULL
<	NULL
25	NULL
s	NULL
37.5	NULL
o	NULL
1	NULL
23	NULL
37.5	NULL
5	NULL
(	NULL
Thel	NULL
,	NULL
U/ml	NULL
J	NULL
325	NULL
32.5	NULL
B	NULL
®	NULL
P	NULL
$	NULL
ars	NULL
J	NULL
275	NULL
o	NULL
3	NULL
m	NULL
22.5	NULL
ai	NULL
22.5	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
[	NULL
s	NULL
)	NULL
42.5	NULL
425	NULL
2	NULL
<	NULL
srs	NULL
37.5	NULL
B	NULL
E	NULL
2	NULL
25	NULL
y	NULL
325	NULL
3	NULL
:	NULL
&	NULL
EY	NULL
i	NULL
$	NULL
ars	NULL
275	NULL
o	NULL
3	NULL
S	NULL
22.5	NULL
22.5	NULL
i	NULL
___	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
0	NULL
so	NULL
60	NULL
90	NULL
120	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
sec	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
increase	NULL
in	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
induced	NULL
by	NULL
thrombin	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
loaded	NULL
with	NULL
indo-1	NULL
,	NULL
and	NULL
the	NULL
increase	NULL
in	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
induced	NULL
by	NULL
thrombin	NULL
was	NULL
monitored	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
.	NULL

A	NULL
,	NULL
time	NULL
courses	NULL
of	NULL
increases	NULL
in	NULL
(	NULL
Ca®*	NULL
)	NULL
;	NULL
at	NULL
different	NULL
thrombin	NULL
concentrations	NULL
(	NULL
0.1	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
0.3	NULL
(	NULL
A	NULL
)	NULL
,	NULL
0.6	NULL
(	NULL
@	NULL
)	NULL
,	NULL
1	NULL
(	NULL
0	NULL
)	NULL
,	NULL
2	NULL
(	NULL
®	NULL
,	NULL
3	NULL
units/ml	NULL
(	NULL
O	NULL
)	NULL
)	NULL
.	NULL

Inset	NULL
,	NULL
concentration-response	NULL
curve	NULL
for	NULL
the	NULL
thrombin	NULL
effect	NULL
.	NULL

B	NULL
,	NULL
time	NULL
course	NULL
of	NULL
the	NULL
thrombin	NULL
effect	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EGTA	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
5	NULL
min	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
®	NULL
)	NULL
of	NULL
2.5	NULL
mm	NULL
EGTA	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
3	NULL
units/ml	NULL
thrombin	NULL
.	NULL

C	NULL
,	NULL
DFP-thrombin	NULL
fails	NULL
to	NULL
increase	NULL
[	NULL
Ca®+*	NULL
]	NULL
;	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Thrombin	NULL
was	NULL
pretreated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
DFP	NULL
(	NULL
1	NULL
mm	NULL
)	NULL
(	NULL
@	NULL
)	NULL
or	NULL
10	NULL
mm	NULL
(	NULL
C	NULL
)	NULL
)	NULL
before	NULL
Ca*+*	NULL
determination	NULL
.	NULL

Thrombin	NULL
(	NULL
O	NULL
)	NULL
or	NULL
DFP-treated	NULL
thrombin	NULL
was	NULL
added	NULL
at	NULL
zero	NULL
time	NULL
.	NULL

D	NULL
,	NULL
hirudin	NULL
and	NULL
anti-thrombin	NULL
III	NULL
block	NULL
the	NULL
thrombin	NULL
response	NULL
.	NULL

Thrombin	NULL
was	NULL
pretreated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
2-fold	NULL
excess	NULL
of	NULL
either	NULL
hirudin	NULL
or	NULL
anti-thrombin	NULL
III	NULL
before	NULL
Ca®*	NULL
determination	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
thrombin	NULL
(	NULL
0	NULL
)	NULL
,	NULL
anti-thrombin	NULL
III	NULL
(	NULL
A	NULL
)	NULL
,	NULL
hirudin	NULL
(	NULL
@	NULL
)	NULL
,	NULL
anti-thrombin	NULL
III-thrombin	NULL
(	NULL
0	NULL
)	NULL
,	NULL
and	NULL
hirudin-thrombin	NULL
complexes	NULL
(	NULL
BB	NULL
)	NULL
were	NULL
then	NULL
monitored	NULL
.	NULL

20	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
6	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
nondenaturating	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
electrophoresis	NULL
buffer	NULL
used	NULL
was	NULL
0.25	NULL
x	NULL
TBE	NULL
.	NULL

The	NULL
dried	NULL
gels	NULL
were	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
using	NULL
intensifying	NULL
screens	NULL
for	NULL
at	NULL
least	NULL
24	NULL
h.	NULL
CD69	NULL
Expression-Jurkat	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
RPMI	NULL
,	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
with	NULL
or	NULL
without	NULL
10	NULL
ug/ml	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
IOT3	NULL
,	NULL
Immunotech	NULL
,	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
3	NULL
units/ml	NULL
thrombin	NULL
,	NULL
100	NULL
um	NULL
TRP	NULL
,	NULL
or	NULL
a	NULL
suboptimal	NULL
concentration	NULL
of	NULL
PMA	NULL
(	NULL
0.5	NULL
ng/ml	NULL
)	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
0.1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
0.01	NULL
%	NULL
NaN3	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
containing	NULL
a	NULL
1:200	NULL
dilution	NULL
of	NULL
phycoerythrin-conjugated	NULL
anti-CD69	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Beckton	NULL
Dickinson	NULL
)	NULL
for	NULL
60	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

After	NULL
three	NULL
washes	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
cells	NULL
were	NULL
analyzed	NULL
using	NULL
an	NULL
ATC	NULL
3000	NULL
eytofluorograph	NULL
(	NULL
ODAM	NULL
,	NULL
Wissembourg	NULL
,	NULL
France	NULL
)	NULL
.	NULL

IL2	NULL
Production	NULL
and	NULL
Quantification-Jurkat	NULL
T	NULL
cells	NULL
or	NULL
peripheral	NULL
mononuclear	NULL
cells	NULL
(	NULL
10¢/m1l	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
RPMI	NULL
,	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
activated	NULL
with	NULL
10	NULL
ug/ml	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
either	NULL
thrombin	NULL
3	NULL
units/ml	NULL
or	NULL
100	NULL
pum	NULL
TRP	NULL
and	NULL
incubated	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Supernatants	NULL
from	NULL
stimulated	NULL
cells	NULL
were	NULL
distributed	NULL
in	NULL
96-well	NULL
microtiter	NULL
plates	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
fresh	NULL
RPMIfetal	NULL
calf	NULL
serum	NULL
before	NULL
determining	NULL
the	NULL
level	NULL
of	NULL
IL2	NULL
by	NULL
an	NULL
enzyme	NULL
immunoassay	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Ferrua	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

RESULTS	NULL
Thrombin	NULL
Induces	NULL
[	NULL
Ca	NULL
``	NULL
*	NULL
]	NULL
Increase	NULL
in	NULL
Jurkat	NULL
T	NULL
Cells-Thrombin	NULL
was	NULL
found	NULL
to	NULL
significantly	NULL
and	NULL
reproducibly	NULL
increase	NULL
cytosolic	NULL
free	NULL
calcium	NULL
concentrations	NULL
in	NULL
the	NULL
human	NULL
T	NULL
leukemic	NULL
cell	NULL
line	NULL
Jurkat	NULL
.	NULL

Fig	NULL
.	NULL

1A	NULL
shows	NULL
a	NULL
time	NULL
course	NULL
of	NULL
the	NULL
increase	NULL
in	NULL
[	NULL
Ca®*1	NULL
;	NULL
induced	NULL
by	NULL
thrombin	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
external	NULL
calcium	NULL
,	NULL
thrombin	NULL
induced	NULL
a	NULL
transient	NULL
rise	NULL
in	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
that	NULL
peaked	NULL
at	NULL
15-20	NULL
s	NULL
and	NULL
rapidly	NULL
declined	NULL
to	NULL
the	NULL
basal	NULL
level	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
50	NULL
50	NULL
A	NULL
B	NULL
b	NULL
3	NULL
45	NULL
as	NULL
|	NULL
.	NULL

<	NULL
3	NULL
40	NULL
3	NULL
40	NULL
|-G	NULL
ss	NULL
&	NULL
&	NULL
35	NULL
}	NULL
g	NULL
so	NULL
§	NULL
30	NULL
3	NULL
26	NULL
E	NULL
a	NULL
a	NULL
20	NULL
A_	NULL
...	NULL
25	NULL
+	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
0	NULL
50	NULL
100	NULL
_	NULL
150	NULL
200	NULL
Time	NULL
:	NULL
see	NULL
[	NULL
Peptide	NULL
]	NULL
,	NULL
M	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

TRP	NULL
mimics	NULL
thrombin-induced	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
rise	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
time	NULL
course	NULL
of	NULL
the	NULL
TRP	NULL
effect	NULL
.	NULL

Experimental	NULL
conditions	NULL
were	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
(	NULL
@	NULL
)	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
(	NULL
O	NULL
)	NULL
was	NULL
added	NULL
at	NULL
time	NULL
0	NULL
.	NULL

B	NULL
,	NULL
concentration-response	NULL
curve	NULL
for	NULL
TRP	NULL
effect	NULL
.	NULL

Cells	NULL
were	NULL
loaded	NULL
with	NULL
indo-1	NULL
and	NULL
treated	NULL
with	NULL
various	NULL
concentration	NULL
of	NULL
TRP	NULL
.	NULL

Fluorescence	NULL
ratio	NULL
(	NULL
at	NULL
each	NULL
concentration	NULL
of	NULL
peptide	NULL
)	NULL
were	NULL
computed	NULL
every	NULL
15	NULL
s.	NULL
The	NULL
values	NULL
reported	NULL
on	NULL
the	NULL
figure	NULL
correspond	NULL
to	NULL
a	NULL
15-s	NULL
stimulation	NULL
.	NULL

within	NULL
1-2	NULL
min	NULL
.	NULL

Thrombin	NULL
increased	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
with	NULL
an	NULL
EC	NULL
;	NULL
,	NULL
of	NULL
0.3	NULL
unit/ml	NULL
(	NULL
3	NULL
nm	NULL
)	NULL
and	NULL
a	NULL
maximum	NULL
at	NULL
1-3	NULL
units/ml	NULL
(	NULL
10-30	NULL
nu	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
inset	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
external	NULL
calcium	NULL
(	NULL
EGTA-treated	NULL
cells	NULL
)	NULL
,	NULL
the	NULL
time	NULL
course	NULL
of	NULL
calcium	NULL
mobilization	NULL
by	NULL
3	NULL
units/ml	NULL
thrombin	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
obtained	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
external	NULL
calcium	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Thrombin-induced	NULL
[	NULL
Ca**	NULL
]	NULL
,	NULL
;	NULL
increase	NULL
was	NULL
strongly	NULL
inhibited	NULL
when	NULL
diisopropyl	NULL
fluorophosphate	NULL
(	NULL
DFP	NULL
)	NULL
-treated	NULL
thrombin	NULL
was	NULL
used	NULL
in	NULL
place	NULL
of	NULL
thrombin	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
anti-thrombin	NULL
III	NULL
and	NULL
hirudin	NULL
,	NULL
two	NULL
potent	NULL
inhibitors	NULL
of	NULL
thrombin	NULL
were	NULL
also	NULL
found	NULL
to	NULL
block	NULL
thrombin	NULL
action	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
7	NULL
amino	NULL
acid	NULL
N-terminal	NULL
thrombin	NULL
receptor	NULL
peptide	NULL
(	NULL
TRP	NULL
;	NULL
SFLLRNP	NULL
)	NULL
,	NULL
an	NULL
agonist	NULL
of	NULL
the	NULL
early	NULL
(	NULL
Vouret-Cravieri	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Hung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
19922	NULL
,	NULL
1992b	NULL
)	NULL
and	NULL
late	NULL
(	NULL
Mac	NULL
Namara	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
biochemical	NULL
events	NULL
triggered	NULL
by	NULL
thrombin	NULL
on	NULL
the	NULL
Ca**	NULL
response	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
the	NULL
time	NULL
course	NULL
of	NULL
the	NULL
increase	NULL
in	NULL
[	NULL
Ca*+*	NULL
]	NULL
;	NULL
triggered	NULL
by	NULL
the	NULL
peptide	NULL
(	NULL
100	NULL
um	NULL
)	NULL
was	NULL
identical	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
thrombin	NULL
.	NULL

The	NULL
dose-response	NULL
curve	NULL
for	NULL
the	NULL
peptide	NULL
's	NULL
effect	NULL
is	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
.	NULL

Maximal	NULL
stimulation	NULL
was	NULL
obtained	NULL
with	NULL
200	NULL
um	NULL
peptide	NULL
,	NULL
while	NULL
the	NULL
half-maximal	NULL
effect	NULL
occurred	NULL
at	NULL
ap-proximatively	NULL
25	NULL
um	NULL
.	NULL

Pertussis	NULL
toxin	NULL
pretreatment	NULL
caused	NULL
only	NULL
a	NULL
partial	NULL
inhibition	NULL
(	NULL
20	NULL
%	NULL
)	NULL
of	NULL
the	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
increase	NULL
induced	NULL
by	NULL
thrombin	NULL
or	NULL
TRP	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

At	NULL
the	NULL
concentration	NULL
used	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
Modesto	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
G-protein	NULL
a	NULL
subunits	NULL
were	NULL
fully	NULL
ADP-ribosylated	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Thrombin	NULL
Induces	NULL
Tyrosine	NULL
Phosphorylation	NULL
of	NULL
Jurkat	NULL
Cellular	NULL
Proteins-Fig	NULL
.	NULL

4	NULL
shows	NULL
the	NULL
time	NULL
course	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
induced	NULL
by	NULL
thrombin	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
analyzed	NULL
by	NULL
immunoblotting	NULL
using	NULL
-	NULL
anti-phosphotyrosine	NULL
-	NULL
antibodies	NULL
.	NULL

Thrombin-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
proteins	NULL
of	NULL
40	NULL
,	NULL
42	NULL
,	NULL
70	NULL
,	NULL
120	NULL
,	NULL
and	NULL
130	NULL
kDa	NULL
.	NULL

Phosphorylation	NULL
was	NULL
rapid	NULL
,	NULL
reaching	NULL
a	NULL
peak	NULL
as	NULL
early	NULL
as	NULL
15-30	NULL
s	NULL
following	NULL
thrombin	NULL
addition	NULL
.	NULL

Differences	NULL
were	NULL
,	NULL
however	NULL
,	NULL
observed	NULL
in	NULL
the	NULL
time	NULL
course	NULL
of	NULL
phosphorylation	NULL
of	NULL
these	NULL
proteins	NULL
.	NULL

While	NULL
phosphorylation	NULL
of	NULL
the	NULL
70-	NULL
,	NULL
120-	NULL
,	NULL
and	NULL
130-kDa	NULL
proteins	NULL
was	NULL
transient	NULL
,	NULL
returning	NULL
to	NULL
basal	NULL
levels	NULL
after	NULL
1	NULL
min	NULL
and	NULL
correlating	NULL
well	NULL
with	NULL
the	NULL
[	NULL
Ca	NULL
#	NULL
+*	NULL
]	NULL
;	NULL
mobilization	NULL
,	NULL
phosphorylation	NULL
of	NULL
the	NULL
40-	NULL
and	NULL
42-kDa	NULL
proteins	NULL
remained	NULL
constant	NULL
for	NULL
at	NULL
least	NULL
10	NULL
min	NULL
.	NULL

Thrombin	NULL
and	NULL
TRP	NULL
Induce	NULL
PKC	NULL
Translocation	NULL
in	NULL
Jurkat	NULL
T	NULL
Cells-Activation	NULL
of	NULL
PKC	NULL
is	NULL
associated	NULL
with	NULL
its	NULL
translocation	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
cell	NULL
membrane	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
of	NULL
PKC	NULL
translocation	NULL
.	NULL

In	NULL
nonstimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
more	NULL
than	NULL
90	NULL
%	NULL
of	NULL
the	NULL
PKC	NULL
activity	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
cytosol	NULL
.	NULL

A	NULL
low	NULL
dose	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/m1	NULL
)	NULL
induced	NULL
a	NULL
redistribution	NULL
of	NULL
PKC	NULL
activity	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
membrane	NULL
(	NULL
approxi-	NULL
8519	NULL
TRP	NULL
Thrombin	NULL
37.5	NULL
<	NULL
I	NULL
s25	NULL
m	NULL
3	NULL
~I	NULL
9	NULL
$	NULL
ars	NULL
A	NULL
o	NULL
as	NULL
&	NULL
2245	NULL
i	NULL
i	NULL
i	NULL
i	NULL
i	NULL
i	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
0	NULL
30	NULL
60	NULL
90	NULL
120	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
see	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
pertussis	NULL
toxin	NULL
on	NULL
the	NULL
rise	NULL
in	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
induced	NULL
by	NULL
thrombin	NULL
and	NULL
TRP	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
10®/ml	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
C	NULL
)	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
ng/m	NULL
!	NULL

(	NULL
EW	NULL
)	NULL
pertussis	NULL
toxin	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
loaded	NULL
with	NULL
indo-1	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
and	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
were	NULL
computed	NULL
every	NULL
15	NULL
s	NULL
as	NULL
described	NULL
above	NULL
.	NULL

-	NULL
200	NULL
com	NULL
C	NULL
ane	NULL
mugs	NULL
csm	NULL
s	NULL
#	NULL
-	NULL
#	NULL
Q	NULL
'	NULL
p	NULL
&	NULL
»	NULL
«	NULL
»	NULL
lls	NULL
2	NULL
2	NULL
a	NULL
-97	NULL
Wits	NULL
-	NULL
ame	NULL
mw	NULL
-	NULL
69	NULL
-	NULL
46	NULL
-	NULL
30	NULL
-21	NULL
kDa	NULL
time	NULL
0	NULL
15	NULL
``	NULL
30	NULL
``	NULL
1°	NULL
5°	NULL
10	NULL
``	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
proteins	NULL
by	NULL
thrombin	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
with	NULL
3	NULL
units/ml	NULL
thrombin	NULL
.	NULL

Proteins	NULL
from	NULL
cell	NULL
lysates	NULL
were	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon	NULL
membranes	NULL
for	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
antibody	NULL
was	NULL
revealed	NULL
by	NULL
'*	NULL
``	NULL
I-protein	NULL
A.	NULL
mately	NULL
50	NULL
%	NULL
in	NULL
each	NULL
fraction	NULL
)	NULL
.	NULL

Thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
and	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
both	NULL
caused	NULL
a	NULL
discernable	NULL
shift	NULL
in	NULL
PKC	NULL
.	NULL

The	NULL
effect	NULL
was	NULL
comparable	NULL
for	NULL
each	NULL
agonist	NULL
,	NULL
following	NULL
10	NULL
min	NULL
of	NULL
thrombin	NULL
receptor	NULL
activation	NULL
,	NULL
cell	NULL
membrane	NULL
associated	NULL
activity	NULL
reached	NULL
approximately	NULL
30	NULL
%	NULL
of	NULL
total	NULL
activity	NULL
.	NULL

Expression	NULL
of	NULL
Thrombin	NULL
Receptor	NULL
mRNA	NULL
by	NULL
Different	NULL
Hematopoietic	NULL
Cell	NULL
Lines-Different	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
were	NULL
examined	NULL
for	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
shows	NULL
that	NULL
a	NULL
cDNA	NULL
probe	NULL
spanning	NULL
part	NULL
of	NULL
the	NULL
coding	NULL
sequence	NULL
of	NULL
the	NULL
hamster	NULL
thrombin	NULL
receptor	NULL
hybridized	NULL
to	NULL
a	NULL
unique	NULL
3.5-kilobase	NULL
transcript	NULL
in	NULL
Jurkat	NULL
(	NULL
leukemic	NULL
T	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
K562	NULL
(	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
)	NULL
,	NULL
and	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
extent	NULL
in	NULL
HPB.ALL	NULL
cells	NULL
(	NULL
immature	NULL
T	NULL
leukemic	NULL
cell	NULL
line	NULL
with	NULL
a	NULL
prothymocyte	NULL
phenotype	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
,	NULL
the	NULL
Chinese	NULL
hamster	NULL
lung	NULL
fibroblast	NULL
cell	NULL
line	NULL
CCL39	NULL
which	NULL
is	NULL
highly	NULL
responsive	NULL
to	NULL
thrombin	NULL
expresses	NULL
considerable	NULL
amounts	NULL
of	NULL
the	NULL
thrombin	NULL
receptor	NULL
transcript	NULL
(	NULL
Rasmussen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Hung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992b	NULL
)	NULL
.	NULL

8520	NULL
100	NULL
7	NULL
{	NULL
R	NULL
Pp	NULL
Membrane	NULL
so	NULL
:	NULL
§§	NULL
§Y	NULL
Cytosol	NULL
¢	NULL
8	NULL
€	NULL
f	NULL
§§	NULL
§r§	NULL
E	NULL
50-	NULL
§§	NULL
§§	NULL
§§	NULL
2	NULL
GN	NULL
n	NULL
a	NULL
20	NULL
.	NULL

§§	NULL
§§	NULL
§§	NULL
§§	NULL
‘	NULL
§	NULL
’	NULL
1	NULL
&	NULL
9	NULL
0	NULL
Treatment	NULL
:	NULL
-	NULL
None	NULL
THR	NULL
TRP	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Thrombin	NULL
and	NULL
TRP	NULL
induced	NULL
PKC	NULL
translocation	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/m1	NULL
)	NULL
,	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
,	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
homogenized	NULL
and	NULL
the	NULL
cytosolic	NULL
and	NULL
membrane	NULL
fractions	NULL
were	NULL
tested	NULL
for	NULL
PKC	NULL
activity	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
PKC	NULL
activity	NULL
in	NULL
each	NULL
fraction	NULL
.	NULL

Values	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
determi-nations	NULL
.	NULL

PMA	NULL
Ccs	NULL
¥	NULL
WKF	NULL
°	NULL
wu	NULL
.	NULL

C	NULL
ao	NULL
@	NULL
*	NULL
COG	NULL
$	NULL
[	NULL
Z	NULL
y	NULL
&	NULL
Thr-R	NULL
--	NULL
gm	NULL
@	NULL
-	NULL
#	NULL
e	NULL
==	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
total	NULL
RNAs	NULL
from	NULL
different	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

Twenty	NULL
five	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
different	NULL
hematopoietic	NULL
cells	NULL
,	NULL
or	NULL
5	NULL
ug	NULL
of	NULL
RNA	NULL
from	NULL
CCL39	NULL
hamster	NULL
lung	NULL
fibroblasts	NULL
,	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
through	NULL
1	NULL
%	NULL
agarose	NULL
.	NULL

RNAs	NULL
were	NULL
transferred	NULL
to	NULL
Hybond	NULL
N+	NULL
membrane	NULL
and	NULL
hybridized	NULL
to	NULL
a	NULL
*°P-labeled	NULL
thrombin	NULL
receptor	NULL
cDNA	NULL
probe	NULL
.	NULL

Autoradiographs	NULL
were	NULL
exposed	NULL
at	NULL
-80	NULL
°C	NULL
for	NULL
5	NULL
days	NULL
,	NULL
except	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
CCL39	NULL
RNA	NULL
(	NULL
2	NULL
days	NULL
)	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
3.5-kilobase	NULL
mRNA	NULL
species	NULL
corresponding	NULL
to	NULL
the	NULL
thrombin	NULL
receptor	NULL
transcript	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
the	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
transcripts	NULL
also	NULL
exhibited	NULL
the	NULL
more	NULL
prominent	NULL
thrombin	NULL
and	NULL
TRP-induced	NULL
increase	NULL
in	NULL
[	NULL
Ca*+*	NULL
]	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

No	NULL
thrombin	NULL
receptor	NULL
message	NULL
was	NULL
detected	NULL
in	NULL
THP1	NULL
(	NULL
my-elomonocytic	NULL
cell	NULL
line	NULL
)	NULL
or	NULL
BL-2	NULL
(	NULL
a	NULL
Burkitt	NULL
lymphoma	NULL
)	NULL
cells	NULL
.	NULL

Accordingly	NULL
,	NULL
THP1	NULL
and	NULL
BL-2	NULL
cells	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
either	NULL
thrombin	NULL
or	NULL
TRP	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
,	NULL
although	NULL
they	NULL
did	NULL
display	NULL
an	NULL
increase	NULL
in	NULL
[	NULL
Ca	NULL
#	NULL
+*	NULL
]	NULL
;	NULL
when	NULL
stimulated	NULL
with	NULL
ATP	NULL
and	NULL
anti-IgM	NULL
receptor	NULL
mAb	NULL
,	NULL
respectively	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
thrombin-induced	NULL
[	NULL
Ca	NULL
#	NULL
+*	NULL
]	NULL
;	NULL
was	NULL
conserved	NULL
in	NULL
a	NULL
CD3-negative	NULL
variant	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
activation	NULL
on	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
different	NULL
times	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

Fig	NULL
.	NULL

8	NULL
indicates	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
decrease	NULL
in	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
levels	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
observed	NULL
as	NULL
soon	NULL
as	NULL
2	NULL
h	NULL
after	NULL
agonist	NULL
addition	NULL
,	NULL
whereas	NULL
virtually	NULL
no	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
was	NULL
detected	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

PMA	NULL
and	NULL
I0T3	NULL
,	NULL
an	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
also	NULL
decreased	NULL
thrombin	NULL
mRNA	NULL
expression	NULL
at	NULL
24	NULL
h.	NULL
In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
lack	NULL
of	NULL
thrombin	NULL
receptor	NULL
expression	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
loss	NULL
of	NULL
thrombin	NULL
responsiveness	NULL
,	NULL
control	NULL
and	NULL
24-h	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
increase	NULL
their	NULL
[	NULL
Ca	NULL
#	NULL
+*	NULL
]	NULL
;	NULL
levels	NULL
following	NULL
thrombin	NULL
or	NULL
TRP	NULL
treatment	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
failed	NULL
to	NULL
induce	NULL
[	NULL
Ca*+*	NULL
]	NULL
;	NULL
increase	NULL
in	NULL
PHA	NULL
plus	NULL
PMA-stimulated	NULL
T	NULL
cells	NULL
,	NULL
demonstrating	NULL
that	NULL
activated	NULL
T	NULL
cells	NULL
become	NULL
refractory	NULL
to	NULL
peptide	NULL
or	NULL
thrombin	NULL
action	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
diminution	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
,	NULL
the	NULL
[	NULL
Ca*+*	NULL
]	NULL
,	NULL
response	NULL
was	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
70	NULL
70	NULL
JK	NULL
CD3+	NULL
JK	NULL
CD3-3	NULL
60	NULL
}	NULL
60	NULL
}	NULL
<	NULL
3	NULL
so	NULL
}	NULL
50	NULL
}	NULL
®	NULL
m	NULL
3	NULL
40	NULL
}	NULL
40	NULL
|-o	NULL
pa	NULL
g	NULL
30	NULL
30	NULL
&	NULL
€	NULL
P	NULL
€	NULL
b	NULL
20	NULL
i	NULL
i	NULL
i	NULL
20	NULL
i	NULL
i	NULL
i	NULL
o	NULL
30	NULL
60	NULL
90	NULL
120	NULL
o	NULL
so	NULL
60	NULL
90	NULL
120	NULL
70	NULL
.	NULL

70	NULL
HPBALL	NULL
K562	NULL
2	NULL
60	NULL
60	NULL
}	NULL
<	NULL
4	NULL
&	NULL
50	NULL
50	NULL
}	NULL
m	NULL
$	NULL
5	NULL
40	NULL
7	NULL
2	NULL
§	NULL
so	NULL
E	NULL
20	NULL
i	NULL
T	NULL
I	NULL
o	NULL
30	NULL
60	NULL
90	NULL
120	NULL
70	NULL
70	NULL
THP1	NULL
BL2	NULL
»	NULL
60	NULL
}	NULL
60	NULL
}	NULL
<	NULL
€	NULL
50	NULL
}	NULL
50	NULL
}	NULL
&	NULL
m	NULL
3	NULL
40	NULL
}	NULL
40	NULL
|	NULL
Fi	NULL
f	NULL
s	NULL
#	NULL
0	NULL
}	NULL
06	NULL
0000-9000	NULL
=	NULL
E	NULL
‘	NULL
m	NULL
20	NULL
:	NULL
1	NULL
P	NULL
20	NULL
i	NULL
i	NULL
1	NULL
o	NULL
30	NULL
60	NULL
90	NULL
120	NULL
o	NULL
so	NULL
60	NULL
90	NULL
120	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
see	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
thrombin	NULL
or	NULL
TRP	NULL
on	NULL
[	NULL
Ca**	NULL
]	NULL
,	NULL
;	NULL
in	NULL
different	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
used	NULL
were	NULL
the	NULL
leukemic	NULL
T	NULL
cell	NULL
line	NULL
Jurkat	NULL
(	NULL
JK	NULL
CD3*	NULL
)	NULL
and	NULL
a	NULL
variant	NULL
lacking	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
(	NULL
CD3/	NULL
TCR	NULL
)	NULL
expression	NULL
(	NULL
JK	NULL
CD3~	NULL
)	NULL
,	NULL
HPB.ALL	NULL
,	NULL
a	NULL
T	NULL
leukemic	NULL
of	NULL
prothymocyte	NULL
phenotype	NULL
,	NULL
K562	NULL
,	NULL
an	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
,	NULL
THP1	NULL
,	NULL
a	NULL
myelomonocytic	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
BL-2	NULL
,	NULL
a	NULL
Burkitt	NULL
lymphoma	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
loaded	NULL
with	NULL
indo-1	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
(	NULL
@	NULL
)	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
(	NULL
O	NULL
)	NULL
were	NULL
added	NULL
at	NULL
time	NULL
0	NULL
and	NULL
fluorescence	NULL
monitored	NULL
as	NULL
described	NULL
above	NULL
.	NULL

found	NULL
markedly	NULL
decreased	NULL
in	NULL
PMA	NULL
or	NULL
IOT3-treated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
nonstimulated	NULL
highly	NULL
purified	NULL
normal	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
Jurkat	NULL
cells	NULL
,	NULL
activation	NULL
of	NULL
purified	NULL
T	NULL
lymphocytes	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
decrease	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
mRNA	NULL
transcript	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
was	NULL
barely	NULL
discernable	NULL
by	NULL
4	NULL
h	NULL
,	NULL
then	NULL
returned	NULL
to	NULL
the	NULL
basal	NULL
level	NULL
at	NULL
24	NULL
h	NULL
but	NULL
was	NULL
undetectable	NULL
after	NULL
48	NULL
and	NULL
72	NULL
h	NULL
of	NULL
thrombin	NULL
treatment	NULL
.	NULL

Treatment	NULL
of	NULL
Jurkat	NULL
T	NULL
Cells	NULL
with	NULL
Thrombin	NULL
or	NULL
TRP	NULL
Activates	NULL
NF-kB-Jurkat	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
respond	NULL
to	NULL
PMA	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
by	NULL
activation	NULL
of	NULL
NF-kB	NULL
and	NULL
NF-kB-con-trolled	NULL
genes	NULL
.	NULL

The	NULL
experiment	NULL
described	NULL
below	NULL
was	NULL
performed	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
thrombin	NULL
or	NULL
TRP	NULL
were	NULL
able	NULL
to	NULL
activate	NULL
NF-kB	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
various	NULL
concentrations	NULL
of	NULL
thrombin	NULL
(	NULL
0.3-3	NULL
units/ml	NULL
)	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
then	NULL
prepared	NULL
and	NULL
analyzed	NULL
for	NULL
specific	NULL
DNA-binding	NULL
of	NULL
NF-kB	NULL
using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
,	NULL
thrombin	NULL
induced	NULL
a	NULL
dose-dependent	NULL
formation	NULL
of	NULL
a	NULL
protein-DNA	NULL
complex	NULL
(	NULL
lanes	NULL
24	NULL
)	NULL
which	NULL
co-migrated	NULL
with	NULL
the	NULL
complex	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
i.e	NULL
.	NULL

cells	NULL
treated	NULL
with	NULL
PMA	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

The	NULL
maximal	NULL
effect	NULL
was	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
8521	NULL
Treatment	NULL
:	NULL
PHA	NULL
+	NULL
PMA	NULL
PMA	NULL
_	NULL
10T3	NULL
Time	NULL
(	NULL
hrs	NULL
)	NULL
:	NULL
0	NULL
2004	NULL
8	NULL
24	NULL
24	NULL
-	NULL
24	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Loss	NULL
qf	NULL
thrombin	NULL
recgptor	NULL
Thr-R	NULL
-B	NULL
»	NULL
«	NULL
ep	NULL
tas	NULL
«	NULL
»	NULL
mRNA	NULL
expression	NULL
and	NULL
thrombin	NULL
re	NULL
sponse	NULL
upon	NULL
Jurkat	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

A	NULL
,	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
5	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
Actin	NULL
|	NULL
--	NULL
f	NULL
m	NULL
were	NULL
incubated	NULL
for	NULL
different	NULL
times	NULL
(	NULL
0-24	NULL
3	NULL
h	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
a	NULL
combi-	NULL
nation	NULL
of	NULL
PHA	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
IOT3	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
were	NULL
also	NULL
tested	NULL
at	NULL
24	NULL
h.	NULL
For	NULL
each	NULL
condition	NULL
,	NULL
RNA	NULL
samples	NULL
were	NULL
prepared	NULL
and	NULL
25	NULL
ug	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
through	NULL
1	NULL
%	NULL
agarose	NULL
.	NULL

Au	NULL
37.5	NULL
Control	NULL
PHA+PMA	NULL
PMA	NULL
32.5	NULL
27.5	NULL
p	NULL
22.5	NULL
pou	NULL
i	NULL
pe	NULL
z	NULL
~	NULL
*X	NULL
1073	NULL
0	NULL
30	NULL
60	NULL
90	NULL
1200	NULL
30	NULL
60	NULL
90	NULL
1200	NULL
30	NULL
60	NULL
90	NULL
1200	NULL
30	NULL
60	NULL
90	NULL
120	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
see	NULL
Time	NULL
:	NULL
see	NULL
2	NULL
toradiographs	NULL
were	NULL
exposed	NULL
at	NULL
-80	NULL
°C	NULL
for	NULL
<	NULL
1	NULL
week	NULL
.	NULL

B	NULL
,	NULL
effect	NULL
of	NULL
thrombin	NULL
and	NULL
TRP	NULL
on	NULL
r	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
in	NULL
24-h	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

S	NULL
Cells	NULL
activated	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
various	NULL
effectors	NULL
were	NULL
harvested	NULL
and	NULL
g	NULL
loaded	NULL
with	NULL
indo-1	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
throm-	NULL
©	NULL
bin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
(	NULL
O	NULL
)	NULL
or	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
(	NULL
ER	NULL
)	NULL
5	NULL
were	NULL
then	NULL
analyzed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

5	NULL
3	NULL
m	NULL
PHA	NULL
+	NULL
TPA	NULL
Treatment	NULL
72	NULL
48	NULL
-	NULL
24	NULL
4	NULL
2	NULL
0	NULL
Time	NULL
(	NULL
hrs	NULL
)	NULL
dest	NULL
--	NULL
-	NULL
28	NULL
S	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Expression	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Higly	NULL
purified	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
PHA	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
.	NULL

RNA	NULL
samples	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
25	NULL
ug	NULL
were	NULL
loaded	NULL
onto	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

Autoradiograph	NULL
was	NULL
exposed	NULL
at	NULL
-80	NULL
°C	NULL
for	NULL
1	NULL
week	NULL
.	NULL

achieved	NULL
using	NULL
3	NULL
units/ml	NULL
thrombin	NULL
.	NULL

TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
activated	NULL
NF-kB	NULL
to	NULL
the	NULL
same	NULL
extent	NULL
as	NULL
thrombin	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Competition	NULL
analysis	NULL
performed	NULL
with	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
clearly	NULL
identified	NULL
the	NULL
complex	NULL
as	NULL
NF-kB	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Thrombin	NULL
Acts	NULL
as	NULL
an	NULL
Accessory	NULL
Signal	NULL
and	NULL
Synergizes	NULL
with	NULL
TCR	NULL
Cross-linking	NULL
to	NULL
Induce	NULL
CD69	NULL
Expression	NULL
and	NULL
IL2	NULL
Production-T	NULL
cell	NULL
activation	NULL
is	NULL
reflected	NULL
by	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
activation	NULL
of	NULL
the	NULL
thrombin	NULL
receptor	NULL
has	NULL
functional	NULL
consequences	NULL
on	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
thrombin	NULL
on	NULL
CD69	NULL
expression	NULL
and	NULL
IL2	NULL
production	NULL
.	NULL

CD69	NULL
expression	NULL
was	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
Jurkat	NULL
T	NULL
cells	NULL
treated	NULL
for	NULL
18	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
different	NULL
effectors	NULL
.	NULL

Thrombin	NULL
or	NULL
TRP	NULL
alone	NULL
did	NULL
not	NULL
induced	NULL
CD69	NULL
expression	NULL
,	NULL
while	NULL
PMA	NULL
or	NULL
triggering	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
resulted	NULL
in	NULL
CD69	NULL
expression	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Thrombin	NULL
or	NULL
TRP	NULL
synergized	NULL
with	NULL
TCR	NULL
cross-linking	NULL
to	NULL
induce	NULL
CD69	NULL
,	NULL
but	NULL
not	NULL
with	NULL
PMA	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
acted	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
as	NULL
the	NULL
phorbol	NULL
ester	NULL
.	NULL

Since	NULL
IL2	NULL
synthesis	NULL
and	NULL
production	NULL
is	NULL
considered	NULL
as	NULL
an	NULL
index	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
we	NULL
next	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
thrombin	NULL
and	NULL
TRP	NULL
on	NULL
IL2	NULL
production	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
cross-linking	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
or	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
for	NULL
18	NULL
h	NULL
with	NULL
or	NULL
without	NULL
10	NULL
ug/ml	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
either	NULL
3	NULL
units/ml	NULL
thrombin	NULL
or	NULL
100	NULL
um	NULL
TRP	NULL
.	NULL

IL2	NULL
production	NULL
was	NULL
then	NULL
measured	NULL
using	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
.	NULL

Although	NULL
thrombin	NULL
or	NULL
TRP	NULL
when	NULL
added	NULL
alone	NULL
were	NULL
unable	NULL
to	NULL
induce	NULL
IL2	NULL
production	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
when	NULL
added	NULL
together	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
both	NULL
agonists	NULL
significantly	NULL
potentiated	NULL
IL2	NULL
production	NULL
in	NULL
two	NULL
different	NULL
experiments	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
secreted	NULL
IL2	NULL
increased	NULL
2-4-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
thrombin	NULL
or	NULL
TRP	NULL
,	NULL
reaching	NULL
20-30	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
response	NULL
(	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
PMA	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
found	NULL
for	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
,	NULL
ruling	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
thrombin	NULL
effect	NULL
may	NULL
be	NULL
restricted	NULL
to	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

DISCUSSION	NULL
The	NULL
action	NULL
of	NULL
thrombin	NULL
on	NULL
cellular	NULL
components	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
has	NULL
been	NULL
poorly	NULL
documented	NULL
.	NULL

Whereas	NULL
thrombin	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
chemotactic	NULL
for	NULL
monocytes	NULL
(	NULL
Bar-Shavit	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
and	NULL
mitogenic	NULL
for	NULL
mouse	NULL
splenocytes	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1976	NULL
)	NULL
,	NULL
information	NULL
concerning	NULL
the	NULL
effects	NULL
of	NULL
thrombin	NULL
on	NULL
defined	NULL
populations	NULL
of	NULL
T	NULL
lymphocytes	NULL
has	NULL
been	NULL
lacking	NULL
.	NULL

Thrombin	NULL
stimulates	NULL
phospholipase	NULL
C	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
via	NULL
the	NULL
activation	NULL
of	NULL
G-proteins	NULL
(	NULL
Pouysségur	NULL
and	NULL
Seuwen	NULL
(	NULL
1992	NULL
)	NULL
,	NULL
for	NULL
review	NULL
)	NULL
.	NULL

This	NULL
activation	NULL
results	NULL
in	NULL
both	NULL
an	NULL
increase	NULL
in	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
concentrations	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
PKC	NULL
(	NULL
Siess	NULL
,	NULL
1989	NULL
;	NULL
Kroll	NULL
and	NULL
Schafer	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
thrombin	NULL
induced	NULL
a	NULL
transient	NULL
rise	NULL
in	NULL
[	NULL
Ca*+*	NULL
]	NULL
;	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
thrombin	NULL
absolutely	NULL
required	NULL
its	NULL
proteolytic	NULL
activity	NULL
,	NULL
since	NULL
DFP-thrombin	NULL
had	NULL
no	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
thrombin	NULL
receptor	NULL
agonist	NULL
(	NULL
SFLLRNP	NULL
)	NULL
was	NULL
as	NULL
effective	NULL
as	NULL
thrombin	NULL
in	NULL
increasing	NULL
[	NULL
Ca**	NULL
]	NULL
;	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
effect	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
cloned	NULL
thrombin	NULL
receptor	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
TRP	NULL
on	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
increase	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
partially	NULL
inhibited	NULL
by	NULL
pertussis	NULL
toxin	NULL
pretreatment	NULL
,	NULL
suggesting	NULL
that	NULL
in	NULL
these	NULL
cells	NULL
the	NULL
thrombin	NULL
receptor	NULL
may	NULL
be	NULL
coupled	NULL
to	NULL
phospholipase	NULL
C	NULL
via	NULL
different	NULL
G-proteins	NULL
(	NULL
i.e	NULL
.	NULL

pertussis	NULL
toxin-insensitive	NULL
and	NULL
-sensitive	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
situation	NULL
has	NULL
been	NULL
already	NULL
reported	NULL
in	NULL
CCL39	NULL
fibroblasts	NULL
(	NULL
Paris	NULL
and	NULL
Pouysségur	NULL
,	NULL
1986	NULL
)	NULL
and	NULL
in	NULL
thrombin	NULL
receptor-transfected	NULL
CV-1	NULL
cells	NULL
(	NULL
Hung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992b	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
thrombin	NULL
8522	NULL
-a-	NULL
NF-xB	NULL
-a-	NULL
NS	NULL
<	NULL
-	NULL
Free	NULL
probe	NULL
Fic	NULL
.	NULL

10	NULL
.	NULL

Thrombin	NULL
and	NULL
TRP	NULL
activates	NULL
NF-kB	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
various	NULL
concentrations	NULL
of	NULL
thrombin	NULL
(	NULL
0.3-3	NULL
units/ml	NULL
)	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
,	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

From	NULL
top	NULL
to	NULL
bottom	NULL
of	NULL
the	NULL
gel	NULL
,	NULL
arrows	NULL
indicate	NULL
the	NULL
migration	NULL
of	NULL
the	NULL
NF-kB	NULL
complex	NULL
,	NULL
a	NULL
nonspecifically	NULL
retarded	NULL
band	NULL
,	NULL
and	NULL
the	NULL
free	NULL
probe	NULL
,	NULL
respectively	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
3	NULL
units/ml	NULL
thrombin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
nucleotide	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Tasis	NULL
I	NULL
Thrombin	NULL
and	NULL
TRP	NULL
induces	NULL
CD69	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
anti-CD3	NULL
mAb	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
%	NULL
/m1l	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
18	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
,	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
0.5	NULL
ng/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
three	NULL
washes	NULL
,	NULL
phycoerythrin-conjugated	NULL
anti-CD69	NULL
mAb	NULL
was	NULL
added	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Analyses	NULL
were	NULL
performed	NULL
using	NULL
an	NULL
ATC	NULL
3000	NULL
cytofluorimeter	NULL
(	NULL
ODAM	NULL
)	NULL
.	NULL

Cells	NULL
expressing	NULL
Treatment	NULL
CD69	NULL
antigen	NULL
%	NULL
None	NULL
1.2	NULL
%	NULL
0.1	NULL
Thr	NULL
1.3	NULL
x	NULL
0.1	NULL
TRP	NULL
1.5	NULL
*	NULL
0.1	NULL
Coated	NULL
anti-CD3	NULL
46.5	NULL
+	NULL
6.3	NULL
(	NULL
100	NULL
%	NULL
)	NULL
+Thr	NULL
70.0	NULL
+	NULL
3.1	NULL
(	NULL
151	NULL
%	NULL
)	NULL
+TRP	NULL
65.6	NULL
+	NULL
2.2	NULL
(	NULL
141	NULL
%	NULL
)	NULL
+PMA	NULL
90.0	NULL
+	NULL
1.0	NULL
(	NULL
193	NULL
%	NULL
)	NULL
receptor	NULL
may	NULL
be	NULL
coupled	NULL
to	NULL
the	NULL
pertussis	NULL
toxin-insensitive	NULL
Bl	NULL
isozyme	NULL
of	NULL
phospholipase	NULL
C	NULL
via	NULL
a	NULL
Gq	NULL
protein	NULL
(	NULL
Taylor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
platelets	NULL
with	NULL
thrombin	NULL
increases	NULL
[	NULL
Ca*+*	NULL
]	NULL
;	NULL
both	NULL
by	NULL
releasing	NULL
from	NULL
internal	NULL
stores	NULL
and	NULL
by	NULL
allowing	NULL
Ca**	NULL
to	NULL
enter	NULL
the	NULL
cells	NULL
.	NULL

Inositol	NULL
trisphosphate	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
cause	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
Tasue	NULL
II	NULL
Thrombin	NULL
and	NULL
TRP	NULL
synergize	NULL
with	NULL
TCR	NULL
cross-linking	NULL
to	NULL
induce	NULL
IL2	NULL
production	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
Jurkat	NULL
T	NULL
cells	NULL
or	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
18	NULL
h	NULL
with	NULL
thrombin	NULL
(	NULL
3	NULL
units/ml	NULL
)	NULL
,	NULL
TRP	NULL
(	NULL
100	NULL
um	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
0.5	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

The	NULL
IL2	NULL
content	NULL
of	NULL
each	NULL
supernatant	NULL
was	NULL
determined	NULL
in	NULL
triplicate	NULL
using	NULL
an	NULL
enzyme	NULL
immunoassay	NULL
.	NULL

IL2	NULL
production	NULL
(	NULL
ng/ml	NULL
)	NULL
Treatment	NULL
Jurkat	NULL
loan	NULL
ia	NULL
-	NULL
PBL	NULL
Experiment	NULL
1	NULL
Experiment	NULL
2	NULL
None	NULL
ND	NULL
«	NULL
ND	NULL
ND	NULL
Thr	NULL
ND	NULL
ND	NULL
ND	NULL
TRP	NULL
ND	NULL
ND	NULL
ND	NULL
PMA	NULL
ND	NULL
ND	NULL
ND	NULL
Coated	NULL
anti-CD3	NULL
0.21	NULL
+	NULL
0.07	NULL
0.16	NULL
+	NULL
0.01	NULL
0.62	NULL
+	NULL
0.20	NULL
+Thr	NULL
0.73	NULL
+	NULL
0.10	NULL
0.31	NULL
+	NULL
0.10	NULL
1.63	NULL
+	NULL
0.45	NULL
+TRP	NULL
0.41	NULL
+	NULL
0.05	NULL
0.31	NULL
+	NULL
0.03	NULL
2.16	NULL
*	NULL
0.50	NULL
+PMA	NULL
4.10	NULL
+	NULL
0.40	NULL
1.01	NULL
+	NULL
0.01	NULL
8.20	NULL
+	NULL
0.80	NULL
@	NULL
ND	NULL
,	NULL
not	NULL
detectable	NULL
.	NULL

release	NULL
from	NULL
internal	NULL
stores	NULL
,	NULL
whereas	NULL
the	NULL
mechanism	NULL
underlying	NULL
Ca**	NULL
entry	NULL
remains	NULL
unknown	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
for	NULL
the	NULL
existence	NULL
of	NULL
thrombin-activated	NULL
Ca**	NULL
channels	NULL
in	NULL
platelets	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
Hashimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

This	NULL
is	NULL
not	NULL
the	NULL
case	NULL
in	NULL
the	NULL
different	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
we	NULL
have	NULL
tested	NULL
,	NULL
since	NULL
the	NULL
thrombin	NULL
effect	NULL
is	NULL
entirely	NULL
accounted	NULL
for	NULL
by	NULL
a	NULL
release	NULL
from	NULL
internal	NULL
stores	NULL
.	NULL

Production	NULL
of	NULL
diacylglycerol	NULL
and	NULL
subsequent	NULL
activation	NULL
of	NULL
PKC	NULL
are	NULL
also	NULL
the	NULL
consequence	NULL
of	NULL
phospholipase	NULL
C	NULL
activation	NULL
.	NULL

Accordingly	NULL
,	NULL
thrombin	NULL
and	NULL
TRP	NULL
induce	NULL
translocation	NULL
of	NULL
PKC	NULL
from	NULL
the	NULL
cytosol	NULL
to	NULL
the	NULL
plasma	NULL
membrane	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Thrombin	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
also	NULL
induces	NULL
or	NULL
increases	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
cellular	NULL
proteins	NULL
.	NULL

Two	NULL
sets	NULL
of	NULL
proteins	NULL
can	NULL
be	NULL
distinguished	NULL
according	NULL
to	NULL
their	NULL
time	NULL
course	NULL
of	NULL
phosphorylation	NULL
.	NULL

The	NULL
level	NULL
of	NULL
phosphorylation	NULL
of	NULL
the	NULL
40-	NULL
and	NULL
42-kDa	NULL
proteins	NULL
was	NULL
stable	NULL
for	NULL
at	NULL
least	NULL
10	NULL
min	NULL
while	NULL
phosphorylation	NULL
of	NULL
the	NULL
70-	NULL
,	NULL
120-	NULL
,	NULL
and	NULL
130-kDa	NULL
proteins	NULL
was	NULL
transient	NULL
.	NULL

The	NULL
70-kDa	NULL
protein	NULL
whose	NULL
phosphorylation	NULL
parallels	NULL
the	NULL
time	NULL
course	NULL
of	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
may	NULL
correspond	NULL
to	NULL
either	NULL
p70-ZAP	NULL
or	NULL
p72	NULL
syk	NULL
(	NULL
Chan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Kolanus	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
p72	NULL
syk	NULL
is	NULL
tran-siently	NULL
phosphorylated	NULL
upon	NULL
thrombin	NULL
stimulation	NULL
of	NULL
human	NULL
platelets	NULL
(	NULL
Tanigushi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
direct	NULL
identification	NULL
of	NULL
the	NULL
thrombin-induced	NULL
70-kDa	NULL
protein	NULL
as	NULL
p70-ZAP	NULL
or	NULL
p72	NULL
syk	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
.	NULL

Whether	NULL
or	NULL
not	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
70-	NULL
,	NULL
120-	NULL
,	NULL
and	NULL
130-kDa	NULL
protein	NULL
is	NULL
a	NULL
prerequisite	NULL
for	NULL
or	NULL
rather	NULL
a	NULL
consequence	NULL
of	NULL
thrombin-induced	NULL
transient	NULL
Ca*+*	NULL
increase	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Thrombin	NULL
receptor	NULL
is	NULL
expressed	NULL
both	NULL
on	NULL
a	NULL
mature	NULL
(	NULL
Jurkat	NULL
)	NULL
and	NULL
immature	NULL
(	NULL
HPB.ALL	NULL
)	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

Interestingly	NULL
,	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
also	NULL
exhibited	NULL
significant	NULL
amounts	NULL
of	NULL
the	NULL
thrombin	NULL
receptor	NULL
transcript	NULL
.	NULL

The	NULL
transient	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
in	NULL
activated	NULL
purified	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
linked	NULL
to	NULL
cell	NULL
cycle	NULL
regulation	NULL
.	NULL

Cells	NULL
expressing	NULL
the	NULL
highest	NULL
amounts	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
showed	NULL
the	NULL
highest	NULL
response	NULL
to	NULL
thrombin	NULL
and	NULL
TRP	NULL
,	NULL
whereas	NULL
virtually	NULL
no	NULL
response	NULL
was	NULL
detected	NULL
in	NULL
cells	NULL
negative	NULL
for	NULL
receptor	NULL
expression	NULL
.	NULL

This	NULL
observation	NULL
was	NULL
further	NULL
confirmed	NULL
in	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
where	NULL
the	NULL
diminution	NULL
of	NULL
thrombin	NULL
receptor	NULL
mRNA	NULL
expression	NULL
paralleled	NULL
the	NULL
loss	NULL
of	NULL
thrombin	NULL
and	NULL
peptide	NULL
response	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
report	NULL
,	NULL
Trejo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
have	NULL
demonstrated	NULL
that	NULL
thrombin	NULL
induced	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
AP1-DNA	NULL
binding	NULL
activity	NULL
in	NULL
human	NULL
astrocytoma	NULL
cells	NULL
as	NULL
measured	NULL
by	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

We	NULL
report	NULL
in	NULL
the	NULL
present	NULL
study	NULL
that	NULL
thrombin	NULL
and	NULL
TRP	NULL
are	NULL
able	NULL
to	NULL
activate	NULL
NF-kB	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
our	NULL
knowl-	NULL
T	NULL
Cell	NULL
Activation	NULL
by	NULL
Thrombin	NULL
edge	NULL
,	NULL
this	NULL
observation	NULL
represents	NULL
the	NULL
first	NULL
example	NULL
of	NULL
NF-kB	NULL
activation	NULL
by	NULL
thrombin	NULL
.	NULL

Finally	NULL
,	NULL
a	NULL
major	NULL
point	NULL
of	NULL
interest	NULL
of	NULL
our	NULL
study	NULL
is	NULL
that	NULL
thrombin	NULL
and	NULL
TRP	NULL
can	NULL
synergize	NULL
with	NULL
TCR	NULL
cross-linking	NULL
to	NULL
induce	NULL
both	NULL
CD69	NULL
expression	NULL
,	NULL
an	NULL
early	NULL
event	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
IL2	NULL
production	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
uneffective	NULL
alone	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
only	NULL
observed	NULL
in	NULL
experiments	NULL
designed	NULL
to	NULL
mimic	NULL
``	NULL
physiological	NULL
``	NULL
conditions	NULL
(	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
immobilized	NULL
anti-CD3	NULL
mAb	NULL
)	NULL
.	NULL

In	NULL
these	NULL
conditions	NULL
,	NULL
thrombin	NULL
and	NULL
TRP	NULL
mimicked	NULL
in	NULL
part	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
suboptimal	NULL
concentration	NULL
of	NULL
PMA	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
thrombin	NULL
may	NULL
replace	NULL
part	NULL
of	NULL
the	NULL
PMA	NULL
effect	NULL
is	NULL
reinforced	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
a	NULL
combination	NULL
of	NULL
thrombin	NULL
and	NULL
PMA	NULL
does	NULL
not	NULL
induce	NULL
IL2	NULL
production	NULL
.	NULL

Interestingly	NULL
,	NULL
it	NULL
has	NULL
been	NULL
described	NULL
that	NULL
in	NULL
a	NULL
mouse	NULL
T	NULL
cell	NULL
hybridoma	NULL
transfected	NULL
with	NULL
the	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
,	NULL
epidermal	NULL
growth	NULL
factor	NULL
can	NULL
stimulate	NULL
IL2	NULL
production	NULL
induced	NULL
by	NULL
anti-Thy1	NULL
or	NULL
anti-CD3	NULL
mAbs	NULL
,	NULL
while	NULL
epidermal	NULL
growth	NULL
factor	NULL
alone	NULL
was	NULL
uneffective	NULL
(	NULL
Kennedy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Conversly	NULL
,	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
transfection	NULL
of	NULL
the	NULL
muscarinic	NULL
receptor	NULL
leads	NULL
to	NULL
carbachol	NULL
stimulation	NULL
of	NULL
IL2	NULL
production	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
other	NULL
stimuli	NULL
(	NULL
Desai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

It	NULL
is	NULL
conceivable	NULL
that	NULL
this	NULL
apparent	NULL
discrepancy	NULL
may	NULL
only	NULL
reflect	NULL
differences	NULL
in	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
both	NULL
receptors	NULL
(	NULL
endogenous	NULL
thrombin	NULL
receptor	NULL
versus	NULL
transfected	NULL
muscarinic	NULL
receptor	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
data	NULL
confirm	NULL
and	NULL
considerably	NULL
extend	NULL
the	NULL
recently	NULL
reported	NULL
observations	NULL
of	NULL
Tordai	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
that	NULL
thrombin	NULL
and	NULL
TRP	NULL
induce	NULL
Ca**	NULL
mobilization	NULL
and	NULL
PKC	NULL
activation	NULL
in	NULL
some	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
mechanisms	NULL
underlying	NULL
the	NULL
thrombin	NULL
response	NULL
in	NULL
T	NULL
cells	NULL
are	NULL
currently	NULL
under	NULL
investigation	NULL
.	NULL

Acknowledgments-We	NULL
express	NULL
our	NULL
sincere	NULL
thanks	NULL
to	NULL
Raymond	NULL
Mes-catullo	NULL
for	NULL
illustration	NULL
work	NULL
and	NULL
to	NULL
Bernard	NULL
Ferrua	NULL
for	NULL
providing	NULL
the	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
.	NULL

REFERENCES	NULL
Auberger	NULL
,	NULL
P.	NULL
,	NULL
Mary	NULL
,	NULL
D.	NULL
,	NULL
Breittmayer	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Aussel	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Fehlmann	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
289-294	NULL
Bar-Shavit	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Kahn	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Wilner	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
and	NULL
Fenton	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
II	NULL
(	NULL
1983	NULL
)	NULL
Science	NULL
220	NULL
,	NULL
728-731	NULL
Berndt	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Philips	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Ann	NULL
.	NULL

N.	NULL
Y	NULL
,	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

485	NULL
,	NULL
228-239	NULL
Chambard	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Paris	NULL
,	NULL
S.	NULL
,	NULL
U'Allemain	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Pouysségur	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
826	NULL
,	NULL
800-803	NULL
Chan	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Iwaashima	NULL
,	NULL
M.	NULL
,	NULL
Turck	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Weiss	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
649-662	NULL
Chen	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
Teng	NULL
,	NULL
N.	NULL
N.	NULL
H.	NULL
,	NULL
and	NULL
Buchanan	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1976	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

101	NULL
,	NULL
41-46	NULL
Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
Church	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
1991-1995	NULL
8523	NULL
Davis	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

135	NULL
,	NULL
2946-2949	NULL
Digman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebowitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1479	NULL
Desai	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Newton	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Kadlecek	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
848	NULL
,	NULL
66-69	NULL
Ferrua	NULL
,	NULL
B.	NULL
,	NULL
Aussel	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Fehlmann	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
97	NULL
,	NULL
215-217	NULL
Golden	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Brugge	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
901-905	NULL
Grynkiewiz	NULL
,	NULL
G.	NULL
,	NULL
Poenie	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Tsien	NULL
,	NULL
R.	NULL
Y	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260	NULL
,	NULL
3440-3450	NULL
Harnett	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Rigley	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
482-486	NULL
Hashimoto	NULL
,	NULL
Y.	NULL
,	NULL
Ogihara	NULL
,	NULL
A.	NULL
,	NULL
Nakanishi	NULL
,	NULL
S.	NULL
,	NULL
Matsuda	NULL
,	NULL
Y.	NULL
,	NULL
KuroKawa	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Nono-mura	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
17078-17081	NULL
Hung	NULL
,	NULL
D.	NULL
,	NULL
Wong	NULL
,	NULL
Y.	NULL
H.	NULL
,	NULL
Vu	NULL
,	NULL
T.	NULL
K.	NULL
H.	NULL
,	NULL
and	NULL
Coughlin	NULL
,	NULL
S.	NULL
R.	NULL
(	NULL
19922	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
20831-20834	NULL
Hung	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Vu	NULL
,	NULL
T.	NULL
K.	NULL
H.	NULL
,	NULL
Nelken	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Coughlin	NULL
,	NULL
S.	NULL
R.	NULL
(	NULL
1992b	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

116	NULL
,	NULL
827-832	NULL
Imbert	NULL
,	NULL
V.	NULL
,	NULL
Peyron	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Farahi	NULL
Far	NULL
,	NULL
D.	NULL
,	NULL
Mari	NULL
,	NULL
B.	NULL
,	NULL
Auberger	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Rossi	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

297	NULL
,	NULL
163-173	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

134	NULL
,	NULL
663-665	NULL
Kennedy	NULL
,	NULL
I	NULL
C.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
4924-4929	NULL
Kolanus	NULL
,	NULL
W.	NULL
,	NULL
Romeo	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
171-183	NULL
Kroll	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
and	NULL
Schafer	NULL
,	NULL
A.	NULL
I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Blood	NULL
74	NULL
,	NULL
1181-1185	NULL
Mari	NULL
,	NULL
B.	NULL
,	NULL
Checler	NULL
,	NULL
F.	NULL
,	NULL
Ponzio	NULL
,	NULL
G.	NULL
,	NULL
Peyron	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Manie	NULL
,	NULL
S.	NULL
,	NULL
Farahifar	NULL
,	NULL
D.	NULL
,	NULL
Rossi	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Auberger	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
3875-3885	NULL
Mac	NULL
Namara	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Sarembock	NULL
,	NULL
I.	NULL
J.	NULL
,	NULL
Gimple	NULL
,	NULL
L.	NULL
W.	NULL
,	NULL
Fenton	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
II	NULL
,	NULL
Coughlin	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
and	NULL
Owens	NULL
,	NULL
G.	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91	NULL
,	NULL
94-98	NULL
Modesto	NULL
,	NULL
J.	NULL
,	NULL
Breittmayer	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Grenier-Brossette	NULL
,	NULL
N.	NULL
,	NULL
Fehlmann	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Cousin	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
.	NULL

Signalling	NULL
8	NULL
,	NULL
25-33	NULL
Osborn	NULL
,	NULL
I.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
2236-2240	NULL
Paris	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Pouysségur	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

5	NULL
,	NULL
55-60	NULL
Pouysségur	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Seuwen	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Physiol	NULL
.	NULL

54	NULL
,	NULL
195-210	NULL
Rasmussen	NULL
,	NULL
U	NULL
.	NULL

B.	NULL
,	NULL
Vouret-Cravieri	NULL
,	NULL
V.	NULL
,	NULL
Jallat	NULL
,	NULL
S.	NULL
,	NULL
Schlesinger	NULL
,	NULL
Y.	NULL
,	NULL
Pages	NULL
,	NULL
G.	NULL
,	NULL
Pavarini	NULL
,	NULL
A.	NULL
,	NULL
Lecocq	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Pouysségur	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Van	NULL
Obberghen-Schilling	NULL
,	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

288	NULL
,	NULL
123-126	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Philips	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Loung	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
and	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
4358-4362	NULL
Shuman	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

485	NULL
,	NULL
228-289	NULL
Siess	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Physiol	NULL
.	NULL

Rev	NULL
.	NULL

69	NULL
,	NULL
58-178	NULL
Tanigushi	NULL
,	NULL
T.	NULL
,	NULL
Kitagawa	NULL
,	NULL
H.	NULL
,	NULL
Yasue	NULL
,	NULL
S.	NULL
,	NULL
Yanagi	NULL
,	NULL
S.	NULL
,	NULL
Sakai	NULL
,	NULL
K.	NULL
,	NULL
Asahi	NULL
,	NULL
M.	NULL
,	NULL
Ohta	NULL
,	NULL
S.	NULL
,	NULL
Takeuchi	NULL
,	NULL
F.	NULL
,	NULL
Nakamura	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Yamamura	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
2277-2279	NULL
Tanti	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Rochet	NULL
,	NULL
N.	NULL
,	NULL
Grémeaux	NULL
,	NULL
T.	NULL
,	NULL
Van	NULL
Obberghen	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Le	NULL
Marchand-Brustel	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

258	NULL
,	NULL
141-146	NULL
Taylor	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Chae	NULL
,	NULL
H.	NULL
Z.	NULL
,	NULL
Rhee	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
and	NULL
Exton	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
850	NULL
,	NULL
516-518	NULL
Tordai	NULL
,	NULL
A.	NULL
,	NULL
Fenton	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
IL	NULL
,	NULL
Andersen	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Gelfand	NULL
E.	NULL
W.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

11	NULL
,	NULL
4876-4886	NULL
Trejo	NULL
,	NULL
J.	NULL
,	NULL
Chambard	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Heller	NULL
Brown	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4742-4750	NULL
Troyer	NULL
,	NULL
D.	NULL
,	NULL
Padilla	NULL
,	NULL
R.	NULL
,	NULL
Smith	NULL
,	NULL
T.	NULL
,	NULL
Kreisberg	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Glass	NULL
,	NULL
W.	NULL
,	NULL
II	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
20126-20131	NULL
Veillette	NULL
,	NULL
A.	NULL
,	NULL
Bookman	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Horak	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
301-308	NULL
Vouret-Cravieri	NULL
,	NULL
V.	NULL
,	NULL
Van	NULL
Obberghen-Schilling	NULL
,	NULL
E.	NULL
,	NULL
Rasmussen	NULL
,	NULL
U	NULL
.	NULL

B.	NULL
,	NULL
Pavarini	NULL
,	NULL
A.	NULL
,	NULL
Lecocq	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Pouysségur	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
Regul	NULL
.	NULL

8	NULL
,	NULL
95-102	NULL
Vouret-Cravieri	NULL
,	NULL
V.	NULL
,	NULL
Van	NULL
Obberghen-Schilling	NULL
,	NULL
E.	NULL
,	NULL
Scimeca	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Van	NULL
Obberghen	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Pouysségur	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

289	NULL
,	NULL
209-214	NULL
Vu	NULL
,	NULL
T.	NULL
K.	NULL
H.	NULL
,	NULL
Hung	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Wheaton	NULL
,	NULL
V	NULL
.	NULL

IL	NULL
.	NULL

,	NULL
and	NULL
Coughlin	NULL
,	NULL
S.	NULL
R.	NULL
(	NULL
1991a	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
1057-1068	NULL
Vu	NULL
,	NULL
T.	NULL
K.	NULL
H.	NULL
,	NULL
Wheaton	NULL
,	NULL
V.	NULL
,	NULL
I.	NULL
,	NULL
Hung	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Charo	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Coughlin	NULL
,	NULL
S.	NULL
R.	NULL
(	NULL
1991b	NULL
)	NULL
Nature	NULL
358	NULL
,	NULL
674-677	NULL

